IP Library › Granted Patent US 12,384,744
Granted Patent B2
US 12,384,744 · App. 17/955,270 · Granted Aug 12, 2025

Enzyme-cleavable methadone prodrugs and methods of use thereof

Inventor: Lynn Kirkpatrick (La Jolla, CA)
Assignee: Ensysce Biosciences Inc.
C07C279/12A61K45/06C07D207/09C07D207/50C07D211/98C07D265/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,384,744
App. No.
17/955,270
Granted
Aug 12, 2025
Kind
B2
Abstract

The present disclosure provides methadone prodrugs, pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a methadone prodrug that provides enzymatically-controlled release of methadone, and an optional enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of methadone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.

Claims (7)

1. Compound MD-112, shown below:

or a salt, hydrate or solvate thereof.

2. A composition comprising:

Compound MD-112:

or a salt, hydrate or solvate thereof; and

a GI enzyme inhibitor.

3. A method comprising administering to a subject the composition of claim 2 .

Assignments (2)
SECURITY INTEREST Recorded Dec 18, 2023
From: ENSYSCE BIOSCIENCES, INC.; EBI OPCO, INC.; EBI OPERATING, INC.; EBIR, INC.
To: 3I, LP
Reel/Frame 065902/0035 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2023
From: KIRKPATRICK, LYNN
To: ENSYSCE BIOSCIENCES INC.
Reel/Frame 062720/0058 →
Continuity (2)
Provisional Application 63250041 · Sep 29, 2021
Related Publication 20230159441A1 · May 25, 2023
References Cited (152)
US 3842064A · Greven · 1974 [cited by applicant]
US 3850904A · Greven · 1974 [cited by applicant]
US 3853836A · Greven · 1974 [cited by applicant]
US 3853838A · Greven · 1974 [cited by applicant]
US 3875137A · Jones et al. · 1975 [cited by applicant]
US 4104371A · Greven et al. · 1978 [cited by applicant]
US 4297346A · Rips et al. · 1981 [cited by applicant]
US 4454338A · Fujii et al. · 1984 [cited by applicant]
US 4532255A · Fujii et al. · 1985 [cited by applicant]
US 5109118A · Mizushima et al. · 1992 [cited by applicant]
US 5217987A · Berger · 1993 [cited by applicant]
US 5352704A · Okuyama et al. · 1994 [cited by applicant]
US 6245802B1 · Iyengar et al. · 2001 [cited by applicant]
US 6388122B1 · Kido et al. · 2002 [cited by applicant]
US 6586196B1 · Bronstein et al. · 2003 [cited by applicant]
US 7060290B1 · Morimoto et al. · 2006 [cited by applicant]
US 7105486B2 · Mickle et al. · 2006 [cited by applicant]
US 7189414B2 · Rubinstein et al. · 2007 [cited by applicant]
US 7223735B2 · Mickle et al. · 2007 [cited by applicant]
US 7655630B2 · Mickle et al. · 2010 [cited by applicant]
US 7893105B2 · Xiang et al. · 2011 [cited by applicant]
US 8163701B2 · Jenkins et al. · 2012 [cited by applicant]
US 8217005B2 · Jenkins et al. · 2012 [cited by applicant]
US 8497237B2 · Jenkins et al. · 2013 [cited by applicant]
US 8569228B2 · Jenkins et al. · 2013 [cited by applicant]
US 8614346B2 · Jass et al. · 2013 [cited by applicant]
US 8685916B2 · Jenkins et al. · 2014 [cited by applicant]
US 8802681B2 · Jenkins et al. · 2014 [cited by applicant]
US 8921418B2 · Jenkins et al. · 2014 [cited by applicant]
US 8962547B2 · Jenkins et al. · 2015 [cited by applicant]
US 9023860B2 · Jenkins et al. · 2015 [cited by applicant]
US 9040032B2 · Jenkins et al. · 2015 [cited by applicant]
US 9095627B2 · Jenkins et al. · 2015 [cited by applicant]
US 9139612B2 · Jenkins et al. · 2015 [cited by applicant]
US 20030035831A1 · Modi · 2003 [cited by applicant]
US 20030180352A1 · Patel et al. · 2003 [cited by applicant]
US 20040063628A1 · Piccariello et al. · 2004 [cited by applicant]
US 20050054561A1 · Mickle et al. · 2005 [cited by applicant]
US 20050080012A1 · Mickle et al. · 2005 [cited by applicant]
US 20050176644A1 · Mickle et al. · 2005 [cited by applicant]
US 20050176645A1 · Mickle et al. · 2005 [cited by applicant]
US 20070042955A1 · Mickle et al. · 2007 [cited by applicant]
US 20070082929A1 · Gant et al. · 2007 [cited by applicant]
US 20070093420A1 · Yeomans et al. · 2007 [cited by applicant]
US 20070123468A1 · Jenkins et al. · 2007 [cited by applicant]
US 20070203055A1 · Mickle et al. · 2007 [cited by applicant]
US 20080139653A1 · Mickle et al. · 2008 [cited by applicant]
US 20090013768A1 · Pouteau et al. · 2009 [cited by applicant]
US 20090136980A1 · Bebbington et al. · 2009 [cited by applicant]
US 20090137618A1 · Jenkins et al. · 2009 [cited by applicant]
US 20090192093A1 · Mickle et al. · 2009 [cited by applicant]
US 20090209569A1 · Arnelle et al. · 2009 [cited by applicant]
US 20100022792A1 · Shen · 2010 [cited by applicant]
US 20100035826A1 · Jenkins et al. · 2010 [cited by applicant]
US 20100080797A1 · Yeomans et al. · 2010 [cited by applicant]
US 20100092562A1 · Hollenbeck et al. · 2010 [cited by applicant]
US 20100227921A1 · Franklin et al. · 2010 [cited by applicant]
US 20100267614A1 · Jenkins · 2010 [cited by applicant]
US 20100286186A1 · Franklin et al. · 2010 [cited by applicant]
US 20110262355A1 · Jenkins et al. · 2011 [cited by applicant]
US 20110262359A1 · Jenkins et al. · 2011 [cited by applicant]
US 20110262360A1 · Jenkins et al. · 2011 [cited by applicant]
US 20110281886A1 · Jenkins et al. · 2011 [cited by applicant]
US 20120178772A1 · Jenkins et al. · 2012 [cited by applicant]
US 20120178773A1 · Jenkins et al. · 2012 [cited by applicant]
US 20120230916A1 · Jenkins et al. · 2012 [cited by applicant]
US 20120270847A1 · Franklin et al. · 2012 [cited by applicant]
US 20130059914A1 · Jenkins et al. · 2013 [cited by applicant]
US 20130210700A1 · Jenkins et al. · 2013 [cited by applicant]
US 20130210701A1 · Jenkins et al. · 2013 [cited by applicant]
US 20130210854A1 · Jenkins et al. · 2013 [cited by applicant]
US 20140121152A1 · Jenkins et al. · 2014 [cited by applicant]
US 20140206597A1 · Jenkins et al. · 2014 [cited by applicant]
US 20150031635A1 · Jenkins et al. · 2015 [cited by applicant]
US 20200009064A1 · Wengner · 2020 [cited by applicant]
DE 1041052 · 1958 [cited by applicant]
DE 1493824 · 1969 [cited by applicant]
EP 1782834 · 2007 [cited by applicant]
EP 2433655 · 2008 [cited by applicant]
GB 1425099 · 1976 [cited by applicant]
WO WO1997012903 · 1997 [cited by applicant]
WO WO2002043767 · 2002 [cited by applicant]
WO WO2004082620 · 2004 [cited by applicant]
WO WO2005032474 · 2005 [cited by applicant]
WO WO2005042772 · 2005 [cited by applicant]
WO WO2007022535 · 2007 [cited by applicant]
WO WO2007120864 · 2007 [cited by applicant]
WO WO2007140272 · 2007 [cited by applicant]
WO WO2008012046 · 2008 [cited by applicant]
WO WO2007120648 · 2008 [cited by applicant]
WO WO2008101187 · 2008 [cited by applicant]
WO WO2008101202 · 2008 [cited by applicant]
WO WO2009067703 · 2009 [cited by applicant]
WO WO2009080030 · 2009 [cited by applicant]
WO WO2009092073 · 2009 [cited by applicant]
WO WO2009136392 · 2009 [cited by applicant]
WO WO2010045599 · 2010 [cited by applicant]
WO WO2010100477 · 2010 [cited by applicant]
WO WO2010148305 · 2010 [cited by applicant]
WO WO2011031350 · 2011 [cited by applicant]
WO WO2011133346 · 2011 [cited by applicant]
WO WO2011133149 · 2011 [cited by applicant]
WO WO2011133178 · 2011 [cited by applicant]
Jenkins, Husfeld et al. (390) Abuse-resistant opioid prodrugs that demonstrate oral overdose protection. The Journal of Pain vol. 13, Issue 4, Supplement , S73, Apr. 2012 (Year: 2012). [cited by examiner]
Zachariah Thomas, MD, and Eduardo Bruera, MD. Use of Methadone in a Highly Tolerant Patient Receiving Parenteral Hydromorphone. Journal of Pain and Symptom Management. vol. 10 No. 4 May 1995. 315-317. (Year: 1995). [cited by examiner]
Duggan (Tetrahedron Letters Ro. 7, pp. 595-598.) (Year: 1979). [cited by examiner]
Bak et al. (1999) “Acyloxyalkoxy-Based Cyclic Prodrugs of Opioid Peptides: Evaluation of the Chemical and Enzymatic Stability as Well as Their Transport Properties Across Caco-2 Cell Monolayers” [cited by applicant]
Bernkop-Schnurch (1998) “The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins” [cited by applicant]
Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations, Guidance for Industry, Food and Drug Administration , published on Oct. 2000. [cited by applicant]
Birk et al. (1976) “Trypsin and chymotrypsin inhibitors from soybeans” [cited by applicant]
Camostat Medilate (http://www.scbt.com/datasheet-203867-camostat-mesylate.html (downloaded on Nov. 14, 2013). [cited by applicant]
Danziger and Dean; (1989) “Automated site-directed drug design: a general algorithm for knowledge acquisition about hydrogen-bonding regions at protein surfaces”; Proc R Soc Lond B Biol Sci. 236(1283); pp. 101-113. [cited by applicant]
Database Internet [Online]Apr. 5, 2005 (Apr. 5, 2005), XP002350634 retrieved from Internet accession No. http://onlineethics.org/reseth/helsinki.html. [cited by applicant]
Database Registry (2001) Abstract, Database accession No. 339089-42-8. [cited by applicant]
De Nardo et al. (1976) “Studies on chemical structure and sweet taste. Note XIII. L-Acylamidosuccinilic acid derivatives” [cited by applicant]
De Nardo et al. (1977) “Studies on chemical structure and sweet taste. Note XIII. L-Acylamidosuccinilic acid derivatives” Database Caplus, Abstract, Database accession No. 1977:119365. [cited by applicant]
Definition of “ex vivo” from thefreedictionary.com, accessed Oct. 7, 2014. [cited by applicant]
Geratz et al. (1976) “Novel bis(benzamidine) compounds with an aromatic central link. Inhibitors of thrombin, pancreatic kallikrein, trypsin, and complement” [cited by applicant]
Göke et al. (1984) “Effect of a Specific Serine Protease Inhibitor on the Rat Pancreas: Systemic Administration of Camostate and Exocrine” [cited by applicant]
Gomes et al. (2007) “Cyclization-activated prodrugs” [cited by applicant]
Gotoh et al. (2005) “The advantages of the Ussing chamber in drug absorption studies” [cited by applicant]
Gottschalk, et al., (2001), “New Concepts inAcute Pain Therapy: Preemptive Analgesia”, American Family Physician, 63(10):1979-1984. [cited by applicant]
Hansch et al. (1990) “Comprehensive Medicinal Chemistry, vol. 5 Biopharmaceutics” [cited by applicant]
Hijikata-Okunomiya et al. (2000) “Selective Inhibition of Trypsin by (2R,4R)-4-Phenyl-1-[N [cited by applicant]
Hyams (downloaded on Nov. 21, 2014 from URL: <http://www.pediatricweb.com/webpost/iframe/MedicalConditions_465.asp?tArticleId=94>). [cited by applicant]
Iwanowicz et al. (2002) “Retro-Binding Thrombin Active Site Inhibitors: Identification of an Orally Active Inhibitor of Thrombin Catalytic Activity” [cited by applicant]
Katragadda et al. (2006) “Simultaneous Modulation of Transport and Metabolism of Acyclovir Prodrugs across Rabbit Cornea: An approach Involving Enzyme Inhibitors” [cited by applicant]
Kunze et al. (1983) “Effects of the serine protease inhibitors FOY and FOY 305 on phospholipase A I (EC 3.1.1.32) activity in rat-liver lysosomes” [cited by applicant]
Lapidus and Sweeney (1973) “L-4′-Cyano-3-(2.2.2-trifluoroacetamideo)s uccinanilic Acid and Related Synthetic Sweetening Agents” [cited by applicant]
Lin et al. (1993) “The 0.25-nm X-ray structure of the Bowman-Birk type inhibitor from mung bean in ternary complex with porcine trypsin” [cited by applicant]
Markwardt et al. (1968) “Comparative studies on the inhibition of trypsin, plasmin, and thrombin by derivatives of benzylamine and benzylamidine” [cited by applicant]
Nafamostat (PubChem, National Center for Biotechnology Information dated Dec. 20, 2005). [cited by applicant]
Nechab et al. (2008) “N-Acylglycinates as acyl donors in serine protease-catalyzed kinetic resolution of amines. Improvement of selectivity and reaction rates.” [cited by applicant]
Opiois911 (downloaded on Nov. 21, 2014 from URL: <http://opioids911.org/safety.php>). [cited by applicant]
Ozawa et al. (1966) “The reactive site of trypsin inhibitors” [cited by applicant]
Pain Doctor (downloaded on Nov. 21, 2014 from URL: <http://paindoctor.com/conditions/common/phantom-limb-pain/>). [cited by applicant]
Pauletti, Giovanni et al. (1997) “Esterase-Sensitive Cyclic Prodrugs of Peptides: Evaluation of a Phenylpropionic Acid Promoiety in a Model Hexapeptide” [cited by applicant]
Perona et a l. (1995) “Structural basis of substrate specificity in the serine proteases”; Protein Science vol. 4; pp. 337-360. [cited by applicant]
Plummer et al. (1997) “Design of peptidomimetic ligands for the pp60srcSH2 domain” [cited by applicant]
Prater et al. (2002) “Successful Pain Management for the Recovering Addicted Patient” [cited by applicant]
Ramjee et al. (2000) “The Kinetic and Structural Characterization of the Reaction of Nafamostat with Bovine Pancreatic Trypsin” [cited by applicant]
Reddy et al. (2012) “An improved process for the preparation of lisdexamfetamine and its pharmaceutically acceptable salts” Database Caplus, Abstract, Database accession No. 2012:654913. [cited by applicant]
Renatus et al. (1998) “Structural and Functional Analyses of Benzamidine-Based Inhibitors in Complex with Trypsin: Implications for the Inhibition of Factor Xa, tPA, and Urokinase” [cited by applicant]
Schanker et al. (1958) “Absorption of drugs from the rat small intestine” [cited by applicant]
Senoo et al. (1966) “Glutamic acid amides” Database Caplus, Abstract, Database accession No. 1966:19804. [cited by applicant]
Simone Joseph; “Oncology (Introduction)” Textbook of Medicine, 20(1), pp. 1004-1010 (Year: 1997). [cited by applicant]
Song, Xiaoping et al. (2002) “Synthesis of a Novel Cyclic Prodrug of RGD Peptidomimetic to Improve Its Cell Membrane Permeation” [cited by applicant]
Tanizawa et al. (1987) “Inverse Substrates for Tryspin and Tryspin-like Enzymes” [cited by applicant]
Testa et al. (2003) “Hydrolysis in Drug and Prodrug Metabolism” Verlag Helvetica Chimica Acta, Postfach, CH-8042, Switzerland, pp. 420-534. [cited by applicant]
Tirkkonen et al. (2004) “Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients” [cited by applicant]
Umezawa (1976) “Structure and activities of protease inhibitors of microbial origin” [cited by applicant]
Van Gelder et al. (2002) “Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures” [cited by applicant]